Coloma Jason V sold $15K of MAZE (indirect holdings)
Coloma Jason V (Chief Executive Officer) sold 553 indirectly-held shares of Maze Therapeutics, Inc. (MAZE) at $26.24 on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The market may briefly react to insider selling headlines, but the presence of a pre-arranged 10b5-1 plan generally dampens fundamental interpretation.
Market read
Primarily a routine insider transaction; any trading impact is likely small and short-lived.
What to watch
The disclosure doesn’t indicate why shares were sold (taxes, diversification, scheduled plan); without additional insider buys/sales context, signal is weak.
Background
This is an SEC Form 4 insider transaction disclosure for Maze Therapeutics, Inc.
Ticker impact
SEC Form 4 shows MAZE CEO Coloma Jason V sold 553 shares in an open-market transaction under a 10b5-1 plan.
Limited near-term impact; any reaction is likely sentiment-driven and small.
The filing is a routine insider transaction with explicit 10b5-1 pre-arrangement, reducing interpretive weight versus discretionary selling.
Market effects
No clear sector read-through from a single, pre-arranged insider sale.
None indicated.
None indicated.
Counterpoint
Even 10b5-1 sales can coincide with management views on near-term valuation, so traders may still fade/trim risk if liquidity is thin.
Key entities
- issuerMaze Therapeutics, Inc.
Company whose CEO executed an open-market sale under a Rule 10b5-1 plan.
- insiderColoma Jason V
CEO and officer/director who sold 553 shares on 2026-06-01.